1925. Prevalence of SARS-CoV-2 Infection in Immunocompromised Patients Following Receipt of Tixagevimab/Cilgavimab

BACKGROUND: Tixagevimab/cilgavimab (TC) was approved by the FDA in December 2021 for use as pre-exposure prophylaxis in patients with moderate to severe immune compromise. On February 24, FDA recommended a second dose for patients who received the original dosing because of decreased activity agains...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Sarah, Morris, Keeley, Fess, Lydia J, Como-Sabetti, Kathy, Lynfield, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752616/
http://dx.doi.org/10.1093/ofid/ofac492.1552

Ejemplares similares

Ejemplares similares